Isolation of bioactive proteins from natural product extracts

从天然产物提取物中分离生物活性蛋白

• 批准号: 10702571
• 负责人: Barry Okeefe
• 金额: $ 78.93万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10702571
• 关键词: 2019-nCoV; Amino Acid Sequence; Antibodies; Clinic; Clinical; Collaborations; Communities; Cyclic Peptides; Evaluation; Extramural Activities; Formulation; Goals; Human; Human Herpesvirus 2; Human papillomavirus 18; Legal patent; Licensing; Ligands; Molecular Target; Natural Products; Nose; Paper; Peptides; Phase I Clinical Trials; Proteins; Publications; Publishing; Reagent; Reporting; Research; Research Project Grants; Rice; Ships; Source; Work; anticancer activity; base; clinical development; in vivo; interest; microbicide; mutant; novel; simian human immunodeficiency virus; success; three dimensional structure

Our efforts have led to the discovery of several classes of bioactive proteins as well as publications on their potential activity. This research has also led to 34 patents overall and significant interest for our discoveries from different licensees. Recent papers of particular interest include our report of fast-dissolving formulations of the protein griffithsin (GRFT) which showed in vivo activity against SHIV, HSV-2 and HPV,18 the expression of GRFT in rice with two other microbicide candidates17 which led to a new patent filing and the discovery of a new class of cyclic peptides called Tyr-lock peptides which also led to a new patent. Additional evidence for the success of PCMBS Project 2 is the fact that two Phase I clinical trials of different versions of the protein GRFT have now been successfully completed one of which whose results have been published. We continue these collaborations to help advance GRFT-based products through the clinic. Finally, two additional Phase I clinical trials of nasal formulations of the QGRFT mutant protein for use against SARS-CoV-2 have been initiated.

我们的努力发现了几类生物活性蛋白质，并发表了有关其潜在活性的出版物。这项研究还总共获得了 34 项专利，不同的被许可人对我们的发现产生了浓厚的兴趣。最近特别令人感兴趣的论文包括我们关于蛋白质格里菲辛 (GRFT) 快速溶解制剂的报告，该制剂显示出体内针对 SHIV、HSV-2 和 HPV 的活性，18 GRFT 与其他两种候选杀菌剂在水稻中的表达17，这导致了新的专利申请和一类新的环肽（称为酪氨酸锁肽）的发现也带来了一项新专利。 PCMBS 项目 2 成功的另一个证据是，不同版本的蛋白质 GRFT 的两项 I 期临床试验现已成功完成，其中一项试验的结果已发表。我们将继续开展这些合作，以帮助推进基于 GRFT 的产品在临床中的应用。最后，针对用于对抗 SARS-CoV-2 的 QGRFT 突变蛋白鼻制剂的另外两项 I 期临床试验已经启动。